Drug Trial Radar · NCT06472908
Efficacy and Safety of Colchicine After PCI
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
8,862
Planned (sponsor's estimate)
Start
Jul 9, 2024
Primary completion
Jun 30, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Colchicine (0.5 mg/day) was recommended by the U.S. Food and Drug Administration in 2023 for the anti-inflammatory treatment of coronary heart disease (CHD). However, colchicine is still not approved for CHD treatment in China. There is no large-scale clinical evidence that colchicine can be used to treat Chinese patients with CHD. Considering the low body weight of the East Asian population, it is unclear whether the recommended standard dose (0.5 mg/day) is suitable for Chinese patients. Therefore, we need to further explore the effects of different doses of colchicine on the efficacy and safety of clinical endpoints in the Chinese population with CHD. This study is a multicenter, prospective, randomized, controlled, double-blind, event-driven clinical study conducted in China. The primary objective of this study is to determine whether long-term treatment with different doses of colchicine reduces the incidence of cardiovascular events in Chinese patients undergoing PCI. The secondary objective is to determine the safety of long-term treatment with different doses of colchicine in this patient population.
Conditions
- Coronary Heart Disease
- Percutaneous Coronary Intervention
- Colchicine
Interventions
Colchicine 0.5 mgDrug
Colchicine 0.5 mg, one pill a day, oral intake
Colchicine 0.375 mgDrug
Colchicine 0.375 mg, one pill a day, oral intake
PlaceboDrug
Placebo, one pill a day, oral intake
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and ischemia-driven revascularizationTime frame: An estimated 2-4 years period
Locations
36 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
The Second Hospital & Clinical Medical School, Lanzhou University
Lanzhou, Gansu, China
The First Affiliated Hospital of Harbin Medical University
Harbin, Harbin, China
Fuwai Huazhong Cardiovascular Hospital
Zhengzhou, Henan, China
The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture
Enshi, Hubei, China
Huangshi Central Hospital
Huangshi, Hubei, China
Jingzhou Central Hospital
Jingzhou, Hubei, China
Dongfeng General Hospital, Hubei University of Medicine
Shiyan, Hubei, China
Shiyan Renmin Hospital
Shiyan, Hubei, China
Taihe hospital
Shiyan, Hubei, China
Suizhou Central Hospital
Suizhou, Hubei, China
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
China Resources and WISCO General Hospital
Wuhan, Hubei, China
Fifth Hospital in Wuhan
Wuhan, Hubei, China
Wuhan Asia Heart Hospital
Wuhan, Hubei, China
Wuhan Central Hospital
Wuhan, Hubei, China
Wuhan First Hospital
Wuhan, Hubei, China
Wuhan Fourth Hospital
Wuhan, Hubei, China
Wuhan Puren Hospital
Wuhan, Hubei, China
Wuhan Sixth Hospital, Affiliated Hospital of Jianghan University
Wuhan, Hubei, China
Wuhan Third Hospital
Wuhan, Hubei, China
Wuhan Wuchang Hospital
Wuhan, Hubei, China
Xiangyang Central Hospital
Xiangyang, Hubei, China
Xiangyang First People's Hospital
Xiangyang, Hubei, China
Xianning Central Hospital
Xianning, Hubei, China
Yichang Central People's Hospital
Yichang, Hubei, China
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China
The General Hospital of Northern Theater Command of the Chinese People's Liberation Army
Shenyang, Liaoning, China
Shandong Provincial Hospital
Jinan, Shandong, China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, China
Songjiang Hospital Affiliated with Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Shanxi Cardiovascular Disease Hospital
Taiyuan, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.